Cargando…

Advances in the application of 3D tumor models in precision oncology and drug screening

Traditional tumor models cannot perfectly simulate the real state of tumors in vivo, resulting in the termination of many clinical trials. 3D tumor models’ technology provides new in vitro models that bridge the gap between in vitro and in vivo findings, and organoids maintain the properties of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Xiaoyong, Huang, Shigao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555934/
https://www.ncbi.nlm.nih.gov/pubmed/36246388
http://dx.doi.org/10.3389/fbioe.2022.1021966
_version_ 1784806960222175232
author Guan, Xiaoyong
Huang, Shigao
author_facet Guan, Xiaoyong
Huang, Shigao
author_sort Guan, Xiaoyong
collection PubMed
description Traditional tumor models cannot perfectly simulate the real state of tumors in vivo, resulting in the termination of many clinical trials. 3D tumor models’ technology provides new in vitro models that bridge the gap between in vitro and in vivo findings, and organoids maintain the properties of the original tissue over a long period of culture, which enables extensive research in this area. In addition, they can be used as a substitute for animal and in vitro models, and organoids can be established from patients’ normal and malignant tissues, with unique advantages in clinical drug development and in guiding individualized therapies. 3D tumor models also provide a promising platform for high-throughput research, drug and toxicity testing, disease modeling, and regenerative medicine. This report summarizes the 3D tumor model, including evidence regarding the 3D tumor cell culture model, 3D tumor slice model, and organoid culture model. In addition, it provides evidence regarding the application of 3D tumor organoid models in precision oncology and drug screening. The aim of this report is to elucidate the value of 3D tumor models in cancer research and provide a preclinical reference for the precise treatment of cancer patients.
format Online
Article
Text
id pubmed-9555934
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95559342022-10-13 Advances in the application of 3D tumor models in precision oncology and drug screening Guan, Xiaoyong Huang, Shigao Front Bioeng Biotechnol Bioengineering and Biotechnology Traditional tumor models cannot perfectly simulate the real state of tumors in vivo, resulting in the termination of many clinical trials. 3D tumor models’ technology provides new in vitro models that bridge the gap between in vitro and in vivo findings, and organoids maintain the properties of the original tissue over a long period of culture, which enables extensive research in this area. In addition, they can be used as a substitute for animal and in vitro models, and organoids can be established from patients’ normal and malignant tissues, with unique advantages in clinical drug development and in guiding individualized therapies. 3D tumor models also provide a promising platform for high-throughput research, drug and toxicity testing, disease modeling, and regenerative medicine. This report summarizes the 3D tumor model, including evidence regarding the 3D tumor cell culture model, 3D tumor slice model, and organoid culture model. In addition, it provides evidence regarding the application of 3D tumor organoid models in precision oncology and drug screening. The aim of this report is to elucidate the value of 3D tumor models in cancer research and provide a preclinical reference for the precise treatment of cancer patients. Frontiers Media S.A. 2022-09-28 /pmc/articles/PMC9555934/ /pubmed/36246388 http://dx.doi.org/10.3389/fbioe.2022.1021966 Text en Copyright © 2022 Guan and Huang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Guan, Xiaoyong
Huang, Shigao
Advances in the application of 3D tumor models in precision oncology and drug screening
title Advances in the application of 3D tumor models in precision oncology and drug screening
title_full Advances in the application of 3D tumor models in precision oncology and drug screening
title_fullStr Advances in the application of 3D tumor models in precision oncology and drug screening
title_full_unstemmed Advances in the application of 3D tumor models in precision oncology and drug screening
title_short Advances in the application of 3D tumor models in precision oncology and drug screening
title_sort advances in the application of 3d tumor models in precision oncology and drug screening
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555934/
https://www.ncbi.nlm.nih.gov/pubmed/36246388
http://dx.doi.org/10.3389/fbioe.2022.1021966
work_keys_str_mv AT guanxiaoyong advancesintheapplicationof3dtumormodelsinprecisiononcologyanddrugscreening
AT huangshigao advancesintheapplicationof3dtumormodelsinprecisiononcologyanddrugscreening